Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4660 | plasma therapy using convalescent plasma with antibody against SARS-CoV-2 Wiki | 0.71 |
| drug1409 | Environmental exposure and clinical features Wiki | 0.71 |
| drug739 | COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.05 |
| D007239 | Infection NIH | 0.03 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
Plasma therapy using convalescent plasma has been shown to be effective in severe acute respiratory syndrome, Ebola virus infection and in H1N1 influenza. More recently there has been a report of the use of convalescent plasma in the treatment of 5 ventilated COVID-19 patients with the suggestion of expedited recovery as the patients improved 1 week after the transfusion. However, this was not a clinical trial and the patients were on other antiviral medication.; therefore, there is a need to undertake such a trial to see if deploying plasma with SARS-CoV-2 neutralizing antibody has utility in managing patients infected with COVID-19 in respiratory distress. The objective of this pilot study is to compare plasma therapy using convalescent plasma with antibody against SARS-CoV-2 to usual supportive therapy in COVID-19 patients with pneumonia and hypoxia, and to determine if the clinical course is improved. The difference between groups will allow an effect size to be determined for a definitive clinical trial.
Description: Could the plasma therapy avoid or delay the need for invasive ventilation
Measure: Requirement for invasive ventilation Time: through study completion up to 28 daysDescription: Through the use of CT values
Measure: Change in viral clearance Time: through study completion up to 28 daysDescription: Chest Xray
Measure: Radiological change Time: through study completion up to 28 daysDescription: As a measure of a change in inflammation
Measure: Change in white cell count Time: through study completion up to 28 daysDescription: A change in C reactive protein as a measure of a change in inflammation
Measure: C reactive protein measurement Time: through study completion up to 28 daysDescription: A change in lactate dehydrogenase as a measure of an improvement in the severity of the disease process
Measure: lactate dehydrogenase measurement Time: through study completion up to 28 daysDescription: A change in procalcitonin as a measure of an improvement in the severity of the disease process
Measure: Procalcitonin measurement Time: through study completion up to 28 daysDescription: A change in D Dimer as a measure of an improvement in the severity of the disease process
Measure: D Dimer measurement Time: through study completion up to 28 daysDescription: A change in Ferritin as a measure of an improvement in the severity of the disease process
Measure: Ferritin measurement Time: through study completion up to 28 daysDescription: A change in troponin T as a measure of an improvement in the severity of the disease process
Measure: Troponin T measurement Time: through study completion up to 28 daysDescription: A change in brain naturetic peptide as a measure of an improvement in the severity of the disease process
Measure: Brain naturetic peptide measurement Time: through study completion up to 28 daysDescription: Mortality rate due to COVID-19
Measure: Mortality rate Time: Up to 28 days of the studyHydroxychloroquine is widely used to treat autoimmune diseases. Clinical investigation has found that a high concentration of cytokines were detected in the plasma of critically ill patients infected with SARS-CoV-2, therefore, hydroxychloroquine as anti-inflammatory agents may reduce this response in accord with their use in autoimmune disease where the cytokine response can be reduced. Favipiravir is an antiviral drug developed in Japan that the data sheet notes that it is a pyrazinecarboxamide derivative with activity against influenza viruses, west nile virus, yellow fever virus, foot and mouth disease virus as well as against flaviviruses, arenaviruses, bunyaviruses and alphaviruses. In February the drug was used for COVID-19 disease in China and was declared effective in treatment, and a report published (in press) comparing Favipiravir with Lopinavir /ritonavir suggested that Favipiravir was superior for prevention of disease progression and viral clearance. The objective of this pilot study is to compare three arms: hydroxychloroquine; favipiravir; standard care (no specific SARS-CoV-2 treatment) only, in symptomatic patients infected by SARS-CoV-2 in an open label randomized clinical trial. The difference between groups will allow an effect size to be determined for a definitive clinical trial.
Description: Single negative SARS-CoV2 PCR NP Swab
Measure: Primary outcome measure will be time to viral clearance Time: Until discharge or for a maximum of 14 days or readmissionDescription: Implementation of escalation of Respiratory Support
Measure: Requirement of Escalation of Respiratory Support Time: Until discharge or for a maximum of 14 days or readmissionDescription: Monitor and document all adverse effects during therapy
Measure: Adverse effects(cardiac, renal, hepatic, hypoglycaemia (defined as RBS <3.9 mmol/L)) Time: Until discharge or for a maximum of 14 days or readmissionDescription: Deterioration of clinical condition requiring ICU admission
Measure: Requirement of ICU Admission Time: Until discharge or for a maximum of 14 days or readmissionDescription: Mortality rate due to COVID-19
Measure: Mortality rate Time: Mortality will be collected up to 30 dayDescription: Determination of the change in lactate levels before and after treatment as a measure of disease activity
Measure: Serum lactate measurement Time: Until discharge or for a maximum of 14 days or readmissionDescription: Determination of the change in ferritin levels before and after treatments as a measure of disease activity
Measure: Serum Ferritin measurement Time: Until discharge or for a maximum of 14 days or readmissionDescription: Determination of the change in D Dimer levels before and after treatments as a measure of disease activity
Measure: Serum D Dimer measurement Time: Until discharge or for a maximum of 14 days or readmissionDescription: Determination of the change in Ratio of Lymphocyte to Neutrophil, before and after treatments as a measure of disease activity
Measure: Ratio of Lymphocyte to Neutrophil, measurement Time: Until discharge or for a maximum of 14 days or readmissionDescription: Patients will be followed during their hospital stay until discharge
Measure: Discharge and Length of Hospital Stay Time: Until discharge or for a maximum of 14 days or readmissionDescription: Capturing readmission data
Measure: Readmission Rate Time: Until 30 days from the start of the trialDescription: SOFA score can identify the critical point at which patients exhibit the highest degree of organ dysfunction
Measure: Daily Sequential Organ Failure Assessment (SOFA) score Time: Until discharge or for a maximum of 14 days or readmissionDescription: NEWS is a tool which improves the detection and response to clinical deterioration in adult patients and is a key element of patient safety and improving patient outcomes
Measure: Daily National Early Warning Score (NEWS) 2 score Time: Until discharge or for a maximum of 14 days or readmissionDescription: its defined as patient discharge or a reduction of 2 points on a 6-point disease severity clinical scale
Measure: Clinical improvement Time: Until discharge or for a maximum of 14 days or readmissionDescription: Determination of the change in QT prolongation, before and after treatments as a measure of disease activity
Measure: QT prolongation Time: Until discharge or for a maximum of 14 days or readmissionDescription: Determination of the change in Cardiac arrythmia (fatal and non fatal), before and after treatments as a measure of disease activity
Measure: Cardiac arrythmia (fatal and non fatal) Time: Until discharge or for a maximum of 14 days or readmissionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports